作者
Huixin Yu, Nielka van Erp, Sander Bins, Ron HJ Mathijssen, Jan HM Schellens, Jos H Beijnen, Neeltje Steeghs, Alwin DR Huitema
发表日期
2017/3
期刊
Clinical pharmacokinetics
卷号
56
页码范围
293-303
出版商
Springer International Publishing
简介
Background and Objective
Pazopanib is a multi-targeted anticancer tyrosine kinase inhibitor. This study was conducted to develop a population pharmacokinetic (popPK) model describing the complex pharmacokinetics of pazopanib in cancer patients.
Methods
Pharmacokinetic data were available from 96 patients from three clinical studies. A multi-compartment model including (i) a complex absorption profile, (ii) the potential non-linear dose–concentration relationship and (iii) the potential long-term decrease in exposure was developed.
Results
A two-compartment model best described pazopanib pharmacokinetics. The absorption phase was modelled by two first-order processes: 36 % (relative standard error [RSE] 34 %) of the administered dose was absorbed with a relatively fast rate (0.4 h−1 [RSE 31 %]); after a …
学术搜索中的文章
H Yu, N van Erp, S Bins, RHJ Mathijssen… - Clinical pharmacokinetics, 2017